Diabetes & Metabolism Journal

Original Article

Complications
Features of Long-Standing Korean Type 2 Diabetes Mellitus Patients with Diabetic Retinopathy: A Study Based on Standardized Clinical Data: Sejeong Park, Sang Youl Rhee, Su Jin Jeong, Kiyoung Kim, Suk Chon, Seung-Young Yu, Jeong-Taek Woo; Diabetes Metab J. 2017;41(5):393-404. Published online September 5, 2017; DOI: https://doi.org/10.4093/dmj.2017.41.5.393

5,093 View
44 Download
16 Web of Science
15 Crossref

Background

This is part of a prospective study carried out as a national project to secure standardized public resources for type 2 diabetes mellitus (T2DM) patients in Korea. We compared various characteristics of long-standing T2DM patients with diabetic retinopathy (DR) and macular edema (ME).

Methods

From September 2014 to July 2015, T2DM patients with disease duration of at least 15 years were recruited at a single university hospital. Clinical data and samples were collected according to the common data elements and standards of procedure developed by the Korean Diabetes Association Research Council. Each participant was assessed by ophthalmologists for DR and ME.

Results

Among 220 registered patients, 183 completed the ophthalmologic assessment. DR was associated with longer disease duration (odds ratio [OR], 1.071; 95% confidence interval [CI], 1.001 to 1.147 for non-proliferative diabetic retinopathy [NPDR]) (OR, 1.142; 95% CI, 1.051 to 1.242 for proliferative diabetic retinopathy [PDR]) and the use of long-acting insulin (OR, 4.559; 95% CI, 1.672 to 12.427 for NPDR) (OR, 4.783; 95% CI, 1.581 to 14.474 for PDR), but a lower prevalence of a family history of cancer (OR, 0.310; 95% CI, 0.119 to 0.809 for NPDR) (OR, 0.206; 95% CI, 0.063 to 0.673 for PDR). ME was associated with higher glycosylated hemoglobin levels (OR, 1.380; 95% CI, 1.032 to 1.845) and the use of rapid-acting insulin (OR, 5.211; 95% CI, 1.445 to 18.794).

Conclusion

Various clinical features were associated with DR and ME. Additional epidemiological and biorepository-based studies using this cohort are being conducted to deepen our understanding of diabetic complications in Korea.

Citations

Citations to this article as recorded by

Diabetic retinopathy related homeostatic dysregulation and its association with mortality among diabetes patients: A cohort study from NHANES
Wenxiang Li, Zhaoguang Lai, Ningning Tang, Fen Tang, Guangyi Huang, Peng Lu, Li Jiang, Daizai Lei, Fan Xu
Diabetes Research and Clinical Practice.2024; 207: 111081. CrossRef
Study on the Interaction Between C3 Gene Polymorphism and Environment in Patients with Type 2 Diabetes Combined with Coronary Artery Disease
Haitang Qiu, Shajidan Abudureyimu, Mengjia Liu, Fen Liu, Ying Gao
Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 1467. CrossRef
Cluster analysis of patient characteristics, treatment modalities, renal impairments, and inflammatory markers in diabetes mellitus
Milena Cojic, Aleksandra Klisic, Amina Sahmanovic, Nemanja Petrovic, Gordana Kocic
Scientific Reports.2024;[Epub] CrossRef
Amino acid analysis as a method of discovering biomarkers for diagnosis of diabetes and its complications
Dan Cai, Biao Hou, Song Lin Xie
Amino Acids.2023; 55(5): 563. CrossRef
The correlation between peripheral complete blood count parameters and diabetic macular edema in proliferative diabetic retinopathy patients: a cross-sectional study
Chunyan Lei, Jinyue Gu, Lili Liu, Keren Zhang, Meixia Zhang
Frontiers in Endocrinology.2023;[Epub] CrossRef
The association between different hypoglycemic regimens and postoperative diabetic macular edema after vitrectomy in the Japanese patients with proliferative diabetic retinopathy
Chunyan Lei, Yun Zhang, Meixia Zhang
Frontiers in Endocrinology.2022;[Epub] CrossRef
Plasma amino acids and oxylipins as potential multi-biomarkers for predicting diabetic macular edema
Sang Youl Rhee, Eun Sung Jung, Dong Ho Suh, Su Jin Jeong, Kiyoung Kim, Suk Chon, Seung-Young Yu, Jeong-Taek Woo, Choong Hwan Lee
Scientific Reports.2021;[Epub] CrossRef
SYSTEMIC FACTORS AND EARLY TREATMENT RESPONSE TO INTRAVITREAL INJECTION FOR DIABETIC MACULAR EDEMA
Hyeseong Hwang, Hwanho Lee, Jin Young Kim, Suhwan Lee, Eoi Jong Seo, Ju Byung Chae, Dong Yoon Kim
Retina.2021; 41(6): 1275. CrossRef
Relationship between Clinical Features of Diabetic Retinopathy and Systemic Factors in Patients with Newly Diagnosed Type II Diabetes Mellitus
Hyeseong Hwang, Jin Young Kim, Tae Keun Oh, Ju Byung Chae, Dong Yoon Kim
Journal of Korean Medical Science.2020;[Epub] CrossRef
Clinical Characteristics and Prevalence of Comorbidities according to Metformin Use in Korean Patients with Type 2 Diabetes
Sang Ouk Chin, In Gyoon Ha, Sang Youl Rhee, Su Jin Jeong, Suk Chon, Sung Hoon Kim, Kyu Jeung Ahn, Sei Hyun Baik, Yongsoo Park, Moon Suk Nam, Kwan Woo Lee, Jeong Taek Woo
International Journal of Endocrinology.2020; 2020: 1. CrossRef
Letter: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)
Jun Sung Moon
Diabetes & Metabolism Journal.2019; 43(6): 911. CrossRef
Prevalence and epidemiological characteristics of patients with diabetic retinopathy in Slovakia: 12-month results from the DIARET SK study
Marta Ondrejkova, Peter Jackuliak, Emil Martinka, Marian Mokan, James Foley, Jana Fabkova, Karol Gecik, Iveta Tvrda, Miroslav Helbich, Monika Gajdosova, Tomislav Bulum
PLOS ONE.2019; 14(12): e0223788. CrossRef
Past and Current Status of Adult Type 2 Diabetes Mellitus Management in Korea: A National Health Insurance Service Database Analysis
Seung-Hyun Ko, Kyungdo Han, Yong-ho Lee, Junghyun Noh, Cheol-Young Park, Dae-Jung Kim, Chang Hee Jung, Ki-Up Lee, Kyung-Soo Ko
Diabetes & Metabolism Journal.2018; 42(2): 93. CrossRef
Letter: Features of Long-Standing Korean Type 2 Diabetes Mellitus Patients with Diabetic Retinopathy: A Study Based on Standardized Clinical Data (Diabetes Metab J 2017;41:393-404)
Jae-Seung Yun
Diabetes & Metabolism Journal.2017; 41(6): 492. CrossRef
Response: Features of Long-Standing Korean Type 2 Diabetes Mellitus Patients with Diabetic Retinopathy: A Study Based on Standardized Clinical Data (Diabetes Metab J 2017;41:393-404)
Sang Youl Rhee, Jeong-Taek Woo
Diabetes & Metabolism Journal.2017; 41(6): 494. CrossRef

Response

Response: Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2016;40:240-7): Sejeong Park, So Young Park, Sang Youl Rhee; Diabetes Metab J. 2016;40(4):336-337. Published online August 18, 2016; DOI: https://doi.org/10.4093/dmj.2016.40.4.336

2,800 View
40 Download

PDF PubReader

Original Article

Others
Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus: Sejeong Park, So Young Park, Yu Jin Kim, Soo Min Hong, Suk Chon, Seungjoon Oh, Jeong-taek Woo, Sung-Woon Kim, Young Seol Kim, Sang Youl Rhee; Diabetes Metab J. 2016;40(3):240-247. Published online April 5, 2016; DOI: https://doi.org/10.4093/dmj.2016.40.3.240

5,279 View
61 Download
5 Web of Science
6 Crossref

Abstract PDF Supplementary Material PubReader

Background

Gastrointestinal (GI) symptoms are common in patients with type 2 diabetes mellitus (T2DM). Rebamipide is an effective gastric cytoprotective agent, but there are few data on its usefulness in T2DM. The aim of this study is to evaluate the improvement of GI symptoms after rebamipide treatment in patients with T2DM.

Methods

Patients with T2DM and atypical GI symptoms were enrolled. They took rebamipide (100 mg thrice daily) for 12 weeks and filled out the diabetes bowel symptom questionnaire (DBSQ) before and after rebamipide treatment. The DBSQ consisted of 10 questions assessing the severity of GI symptoms by a 1 to 6 scoring system. Changes in the DBSQ scores before and after rebamipide treatment were analyzed to evaluate any improvements of GI symptoms.

Results

A total of 107 patients were enrolled, and 84 patients completed the study. The mean age was 65.0±7.8, 26 patients were male (24.8%), the mean duration of T2DM was 14.71±9.12 years, and the mean glycosylated hemoglobin level was 6.97%±0.82%. The total DBSQ score was reduced significantly from 24.9±8.0 to 20.4±7.3 before and after rebamipide treatment (P<0.001). The DBSQ scores associated with reflux symptoms, indigestion, nausea or vomiting, abdominal bloating or distension, peptic ulcer, abdominal pain, and constipation were improved after rebamipide treatment (P<0.05). However, there were no significant changes in symptoms associated with irritable bowel syndrome, diarrhea, and anal incontinence. No severe adverse events were reported throughout the study.

Conclusion

Rebamipide treatment for 12 weeks improved atypical GI symptoms in patients with T2DM.

Citations

Citations to this article as recorded by

Effectiveness of Rebamipide as a part of the Helicobacter pylori eradication therapy in Russia: a meta-analysis of controlled trials
Dmitry N. Andreev, Igor V. Maev, Dmitry S. Bordin, Svetlana V. Lyamina, Diana T. Dicheva, Aleksei K. Fomenko, Armine S. Bagdasarian
Consilium Medicum.2022; 24(5): 333. CrossRef
Сompliance in patients with coronary heart disease and erosive-ulcerative gastroduodenopathy
A. R. Molchanova, A. I. Dolgushina, A. A. Seljanina
Experimental and Clinical Gastroenterology.2020; (6): 82. CrossRef
Rebamipide: evidence base for use in gastroenterology
D. N. Andreev, I. V. Maev
Terapevticheskii arkhiv.2020; 92(12): 97. CrossRef
Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis
Mohamed Hasif Jaafar, Sher Zaman Safi, Maw-Pin Tan, Sanjay Rampal, Sanjiv Mahadeva
Digestive Diseases and Sciences.2018; 63(5): 1250. CrossRef
Letter: Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J2016;40:240-7)
Jin Hwa Kim
Diabetes & Metabolism Journal.2016; 40(4): 334. CrossRef
Response: Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2016;40:240-7)
Sejeong Park, So Young Park, Sang Youl Rhee
Diabetes & Metabolism Journal.2016; 40(4): 336. CrossRef

First
Prev
Page of 1
Next
Last

Search